{
    "clinical_study": {
        "@rank": "146290", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the pharmacokinetics of FF, UMEC and VI administered from one\n      inhaler (at two different strengths of UMEC (125 and 62.5microgram [mcg]) and FF/VI\n      (ICS/LABA) and UMEC/VI (LAMA/LABA).\n\n      Subjects will receive each of the four treatments once, separated by a wash-out period of\n      7-21 days between doses in a four way crossover design. There will be 4 treatment periods in\n      total.  During each treatment period, subjects will attend the clinical unit on Day -1 for\n      standard safety assessments in addition to familiarization with the inhaler.  Each subject\n      will remain resident in the unit until at least 24 hours after the dose given on Day 1.\n      Following completion of all four treatment periods, a follow up visit will take place 7 to\n      21 days following the final dose of study medication."
        }, 
        "brief_title": "Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Safety\n\n          -  Average Corrected QT Interval using Fridericia's formula (QTcF) <450 msec at\n             screening.\n\n          -  Forced Expiratory Volume in 1 second (FEV1) >=80% predicted and a FEV1/Forced Vital\n             Capacity (FVC) ratio >=0.7 at screening.\n\n          -  Alanine transaminase (ALT), alkaline phosphatase and bilirubin <=1.5x Upper Limit\n             Normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated\n             and direct bilirubin <35%).\n\n        Population\n\n          -  Male or female between 18 and 65 years of age inclusive, at the time of signing the\n             informed consent.\n\n          -  Healthy as determined by a responsible and experienced physician, based on a medical\n             evaluation including medical history, physical examination, laboratory tests and lung\n             function testing.  A subject with a clinical abnormality or laboratory parameters\n             outside the reference range for the population being studied may be included only if\n             the Investigator and GSK medical monitor consider the finding is unlikely to\n             introduce additional risk factors and will not interfere with the study procedures\n             and outcome.\n\n          -  Subjects who are current non-smokers who have not used any tobacco products in the\n             6-month period preceding the screening visit and have a pack history of <=10 pack\n             years. [number of pack years = (number of cigarettes per day /20) x number of years\n             smoked]\n\n          -  Capable of giving written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form.\n\n          -  A female subject is eligible to participate as follows: Non-childbearing potential,\n             females on hormone replacement therapy (HRT) and whose menopausal status is in doubt\n             will be required to use one of the contraception methods and women of childbearing\n             potential should have used one of the contraception methods.\n\n          -  Body Mass Index (BMI) within the range 18.0-33.0 kg/m2 (inclusive).\n\n        Exclusion Criteria:\n\n        Safety\n\n          -  Lactating or pregnant females as determined by positive serum or urine hCG test at\n             screening or Day -1.\n\n          -  A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.\n\n        Hepatic Disease\n\n          -  Current or chronic history of liver disease, or known hepatic or biliary\n             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)\n             or a history of regular alcohol consumption within 6 months of the study defined as:\n             an average weekly intake of >14 drinks for males or >7 drinks for females. One drink\n             is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of\n             wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.\n\n        Concurrent Disease\n\n          -  History of respiratory disease (i.e. history of asthmatic symptoms) in the last 10\n             years.\n\n          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody\n             result within 3 months of screening or a positive test for HIV.\n\n        Concurrent Medication\n\n          -  Unable to refrain from the use of prescription or non-prescription drugs, including\n             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or\n             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is\n             longer) prior to the first dose of study medication, unless in the opinion of the\n             Investigator and GSK Medical Monitor the medication will not interfere with the study\n             procedures or compromise subject safety.\n\n        Population\n\n          -  A positive pre-study drug/alcohol screen at screening and Day -1.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product within the following time period prior to the first dosing day in the current\n             study: 30 days, 5 half-lives or twice the duration of the biological effect of the\n             investigational product (whichever is longer), or has had exposure to more than four\n             new chemical entities within 12 months prior to the first dosing day.\n\n          -  History of sensitivity to any of the study medications, or components thereof or a\n             history of drug or other allergy that, in the opinion of the investigator or GSK\n             Medical Monitor, contraindicates their participation.\n\n          -  Unwillingness or inability to follow the procedures outlined in the protocol.\n\n          -  Subject is mentally or legally incapacitated.\n\n          -  The subject is unable to refrain from consumption of red wine, seville oranges,\n             grapefruit or grapefruit juice and pummelos, exotic citrus fruits, grapefruit hybrids\n             or any fruit juices containing these fruits from 7 days prior to the first dose of\n             study medication and for the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894386", 
            "org_study_id": "200587"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4", 
                    "Sequence 1"
                ], 
                "description": "100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)", 
                "intervention_name": "FF 400 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4", 
                    "Sequence 1"
                ], 
                "description": "125 mcg powder for inhalation delivered by DPI", 
                "intervention_name": "UMEC 500 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4", 
                    "Sequence 1"
                ], 
                "description": "62.5 mcg powder for inhalation delivered by DPI", 
                "intervention_name": "UMEC 250 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4", 
                    "Sequence 1"
                ], 
                "description": "25 mcg powder for inhalation delivered by DPI", 
                "intervention_name": "VI 100 mcg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluticasone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GW642444 (Vilanterol)", 
            "GSK573719 (Umeclidinium)", 
            "GW685698 (Fluticasone Furoate)", 
            "pharmacokinetics", 
            "Healthy subjects"
        ], 
        "lastchanged_date": "October 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 Mcg and 100/125/25 Mcg and in Comparison With FF/VI (100/25 Mcg) and UMEC/VI (62.5/25 Mcg).", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Aspire IRB", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)) (or Area under the concentration time curve from time zero (pre-dose) to last common time of quantifiable concentration within a subject across all treatments [AUC(0-t')] if AUC(0-infinity) cannot be determined) and maximum observed concentration (Cmax) for each individual component (UMEC will be dose-normalised) across treatment groups will be estimated using the following treatment ratios: FF/UMEC/VI 100mcg/125mcg /25mcg Versus, FF/UMEC/VI 100mcg /62.5mcg /25mcg", 
                "measure": "Composite of Pharmacokinetic (PK) Parameters as a measure of systemic exposure.", 
                "safety_issue": "No", 
                "time_frame": "PK Blood samples will be collected at  Predose, 3, 5, 7, 10, 15, 12, 15, 30, 45 minutes, 1hour, 1.5, 2, 4, 6, 8, 12, 24 hours post dose on Day 1 of each treatment period"
            }, 
            {
                "description": "FF: FF/UMEC/VI versus FF/VI; UMEC: FF/UMEC/VI versus UMEC/VI; VI: FF/UMEC/VI versus FF/VI; VI: FF/UMEC/VI versus UMEC/VI", 
                "measure": "Systemic exposure of FF and UMEC and VI following single inhaled doses (four inhalations) of FF/UMEC/VI 100mcg /62.5mcg /25mcg compared with FF/VI 100mcg /25mcg and UMEC/VI 62.5mcg /25mcg", 
                "safety_issue": "No", 
                "time_frame": "PK Blood samples will be collected at Day 1 Predose, 3, 5, 7, 10, 15, 12, 15, 30, 45 minutes, 1hour, 1.5, 2, 4, 6, 8, 12, 24 hours post dose."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Elimination half-life of a compound (t\u00bd) and Time after administration of a compound when the maximum plasma concentration is reached (tmax)", 
            "measure": "Composite of PK Parameters.", 
            "safety_issue": "No", 
            "time_frame": "PK Blood samples will be collected at Day 1 Predose, 3, 5, 7, 10, 15, 12, 15, 30, 45 minutes, 1hour, 1.5, 2, 4, 6, 8, 12, 24 hours post dose."
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}